Frontier Pharma: Parkinsons Disease - Identifying and Commercializing First-in-Class Innovation
ALBANY, UNITED STATES - Jun 4, 2015 - Market Research Reports Search Engine (MRRSE) has announced the addition of the Frontier Pharma: Parkinsons Disease - Identifying and Commercializing First-in-Class Innovation report by Market Research Reports Search Engine to its rapidly growing market research report database. The report discusses more than 300 therapies for Parkinsons disease in the pipeline, including over 90 first-in-class therapies. The report segments the pipeline products by phase, molecule type, and therapeutic target.
The report describes the key fact that the mechanism of action of most current and pipeline therapies for Parkinsons disease is different: most current therapies focus on neuromodulatory receptors, whereas a majority of pipeline products act in a neuroprotective fashion, targeting and eliminating dysfunctional disease processes.
The report presents the clinical and commercial landscape of Parkinsons disease, in order to deliver a clear view of the therapeutics and how they would affect the global scenario. It examines the genetic and environmental causes of Parkinsons disease and discusses the pathophysiology of the disease.
Browse Full Report with TOC : http://www.mrrse.com/frontier-pharma-parkinsons-disease
The report details the Parkinsons disease therapeutics markets competitive landscape as one virtually foreign to consolidation. Of the many Parkinsons disease therapeutics brought into the market since 2006, only nine have been developed in a collaborative effort. This is presented as a major growth opportunity for market players in the Parkinsons disease therapeutics market, as collaboration will aid the scientific aspect of the research, helping the companies achieve more precise conclusions.
Apart from collaboration, consistent innovation is presented as a major factor that will aid competitors gain an edge in the highly fragmented market for Parkinsons disease therapeutics. Like any field in medicine, innovation is the one sure way of advancing ahead of competitors on the back of stronger therapeutics with a more effective and more precise action. The innovation of biologic therapeutics, in particular, will be an attractive investment options, as it is a promising field and is supported by financial support from governments.
Among pipeline products, the report particularly details pipeline programs targeting the following factors: LRRK2, progranulin, glial cell-derived neurotrophic factor, cerebral dopamine neurotrophic factor, tyrosine receptor kinase B, mesencephalic astrocyte-derived neurotrophic factor, metabotropic glutamate receptor, DJ-1, C-jun-N-terminal kinases, reactive oxygen species, heat shock proteins, heat shock transcription factor, growth hormone secretagogue receptor, protein phosphasate 2A, and cytochrome P450 2D6.
Compiled by experienced industry experts, the report includes primary and secondary information detailing the trajectory of the market for Parkinsons disease therapeutics and includes insightful inputs from leading experts.
Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 5
2.1 Highly Innovative and Diverse Pipeline 5
2.2 Alignment of Innovation to Disease Processes and Genetics 5
2.3 Deals Landscape Present Substantial Investment Opportunities 5
3 The Case for Innovation 6
3.1 Growing Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 7
3.3 Innovative First-in-Class Product Developments Remain Attractive 7
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8
3.5 Sustained Innovation 8
3.6 GBI Research Report Guidance 9
4 Clinical and Commercial Landscape 10
4.1 Epidemiology 10
4.2 Disease Etiology 11
4.2.1 Exposure to Environmental Toxins 11
4.2.2 Genetic Causes of Familial Parkinsons Disease 11
4.2.3 Susceptibility Genes for Parkinsons Disease 13
4.3 Disease Pathophysiology 13
4.3.1 Basal Ganglia Anatomy and Physiology 13
4.3.2 Processes Underlying Neurodegeneration in Parkinsons Disease 16
4.4 Disease Symptoms 20
4.5 Co-morbidities and Complications 20
4.6 Diagnosis 21
4.6.1 Classification 21
4.7 Prognosis and Disease Staging 23
4.8 Treatment Options 24
4.8.1 Pharmacological Treatment 24
4.8.2 Non-pharmacological Treatments 28
4.9 Marketed Product Overview 28
4.10 Overview of Marketed Products for Parkinsons Disease 29
4.11 Efficacy and Safety of Marketed Products 31
4.12 Treatment Algorithm 33
4.13 Current Unmet Needs 35
5 Assessment of Pipeline Product Innovation 37
5.1 Parkinsons Disease Pipeline by Molecule Type, Phase and Therapeutic Targets 37
5.2 Comparative Distribution of Programs between the Parkinsons Disease Market and Pipeline by Therapeutic Target Family 41
Send An Enquiry :http://www.mrrse.com/enquiry/131
6 Signaling Network, Parkinsons Disease Genetics and Innovation Alignment 46
6.1 The Complexity of Signaling Network in Central Nervous System 46
6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration 47
6.3 First-in-Class Target Matrix Assessment 51
7 First-in-Class Target and Pipeline Program Evaluation 54
7.1 Overview of Pipeline Programs Targeting ?-synuclein 54
7.2 Overview of Pipeline Programs Targeting LRRK2 57
7.3 Overview of Pipeline Programs Targeting Glial Cell-Derived Neurotrophic Factor 60
7.4 Overview of Pipeline Programs Targeting Progranulin 63
7.5 Overview of Pipeline Programs Targeting Cerebral Dopamine Neurotrophic Factor 66
7.6 Overview of Pipeline Programs Targeting Mesencephalic Astrocyte-Derived Neurotrophic Factor 68
7.7 Overview of Pipeline Programs Targeting Tyrosine Receptor Kinase B 70
7.8 Overview of Pipeline Programs Targeting Metabotropic Glutamate Receptor 4 73
7.9 Overview of Pipeline Programs Targeting Metabotropic Glutamate Receptor 8 75
7.10 Overview of Pipeline Programs Targeting C-jun-N-Terminal Kinases 76
7.11 Overview of Pipeline Programs Targeting DJ-1 79
7.12 Overview of Pipeline Programs Targeting Reactive Oxygen Species 80
7.13 Overview of Pipeline Programs Targeting Heat Shock Transcription Factor 1 82
7.14 Overview of Pipeline Programs Targeting Heat Shock Protein 90 84
7.15 Overview of Pipeline Programs Targeting Growth Hormone Secretagogue Receptor 86
7.16 Overview of Pipeline Programs Targeting Protein Phosphatase 2A 88
7.17 Overview of Pipeline Programs Targeting Cytochrome P450 2D6 90
7.18 Conclusion 91
8 Deals and Strategic Consolidations 93
8.1 Industry-wide First-in-Class Deals 93
8.2 Parkinsons Disease Deals Landscape 95
8.3 Licensing Deals 95
8.3.1 Molecule Type 97
8.3.2 Mechanism of Action 97
8.4 Co-development Deals 100
8.4.1 Mechanism of Action 101
8.5 First-in-Class Programs Not Involved in Licensing or Co-Development Deals 103
9 Appendix 106
9.1 Abbreviations 106
9.2 References 108
9.3 Contact Us 121
9.4 Disclaimer 121
Letest Report :
- Diisopropanolamine (DIPA) Market - Global Industry Expert Opinions Analysis, Emerging Opportunities, Market Size, Share, Growth Drivers, Market Trends, Statistics And Forecast 2015 - 2020
http://www.mrrse.com/diisopropanolamine-market
Diisopropanolamine (DIPA) is one of the basic chemicals that is used as an emulsifier, intermediate, neutralizer and stabilizer in many applications for achieving alkalinity, basicity and buffering objectives. The good stabilizing properties of diisopropanolamine (DIPA) for fat and oil, it is widely used for neutralization of sulfonic acid-based surfactants and fatty acids. The major applications of diisopropanolamine (DIPA) include metalworking and personal care products. However, diisopropanolamine (DIPA) also finds applications in coatings, paint strippers, pesticides, photographic intermediates, paper, polyurethane additives, plastics, reaction intermediates, textiles, urethanes and surfactants.
In personal care market, diisopropanolamine (DIPA) is used for pH contributor, neutralization of acidic compounds. Owing to its better surfactant properties, diisopropanolamine (DIPA) is used as an emulsifying agent, clean contributor, wetting agent, viscosity and lubrication. The demand for diisopropanolamine (DIPA) for personal care application is expected to garner high demand in the near future. The growth for diisopropanolamine (DIPA) used in personal care applications can be attributed to the growing use of personal care products across the globe. The personal care industry is expected to witness robust growth especially in Asia Pacific countries. Increasing disposable income in this region and growing exposure towards personal care products is expected to boost the demand for diisopropanolamine (DIPA) used in personal care products. Diisopropanolamine (DIPA) is used as tall oil amides in water based metalworking fluids.
- Sodium Hydrosulfide Market - Global Industry Expert Opinions Analysis, Emerging Opportunities, Market Size, Share, Growth Drivers, Market Trends, Statistics And Forecast 2015 - 2020
http://www.mrrse.com/sodium-hydrosulfide-market
Sodium hydrosulfide is a chemical compound that is represented using the formula NaHS. Sodium hydrosulfide is colorless or yellow crystals. The compound has a melting point at 350oC. Sodium hydrosulfide is readily soluble in alcohol and water. Sodium hydrosulfide has a molecular mass of 56.6. The aqueous solution of sodium hydrosulfide usually has alkaline reactions. Sodium hydrosulfide is a compound that is formed by neutralizing hydrogen sulfide with sodium hydroxide. Sodium hydrosulfide is an essential reagent that is used for the synthesis of inorganic and organic sulfur compound. Sodium hydrosulfide is solid in nature; however, it is often used as an aqueous solution. Solid sodium hydrosulfide is highly hygroscopic in nature. However, sodium hydrosulfide is more stable in solutions as they get slowly oxidized in air. Sodium hydrosulfide when in solid state is colorless and smells like that of hydrogen sulfide due to its hydrolysis by moisture present in the atmosphere. In contrast, to that of sodium sulfide, which is insoluble in organic solvents sodium hydrosulfide, is highly soluble in organic solvents. Sodium hydrosulfide in its crystalline form undergoes two phase transitions. Sodium hydrosulfide adopts sodium chloride structure at temperature above 300K. Sodium hydrosulfide liberates hydrogen sulfide when heated under the action of acids which act as reducing agents. Sodium hydrosulfide is synthesized in the laboratory by treating sodium methoxide with hydrogen sulfide. Sodium hydrosulfide is unique alkaline product that has a wide range of industrial applications.
About Us
Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. Headquartered in New York, U.S., MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSEs repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.
Contact Us:
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
Email: sales@mrrse.com
Website: http://www.mrrse.com/